MA35638B1 - 2-thiopyrimidinones - Google Patents

2-thiopyrimidinones

Info

Publication number
MA35638B1
MA35638B1 MA37018A MA37018A MA35638B1 MA 35638 B1 MA35638 B1 MA 35638B1 MA 37018 A MA37018 A MA 37018A MA 37018 A MA37018 A MA 37018A MA 35638 B1 MA35638 B1 MA 35638B1
Authority
MA
Morocco
Prior art keywords
inhibitors
thiopyrimidinones
treating
pharmaceutical compositions
compositions containing
Prior art date
Application number
MA37018A
Other languages
English (en)
Inventor
Yan Zhang
Roger Benjamin Ruggeri
Daniel Wei-Shung Kung
Philip Albert Carpino
Edward Lee Conn
Benjamin Neil Rocke
Joseph Scott Warmus
Rober T Lee Dow
Matthew Scott Dowling
Suvi Tuula Marjukka Orr
Matthew Forrest Sammons
David Hepworth
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47356235&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA35638(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of MA35638B1 publication Critical patent/MA35638B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

L'invention concerne des inhibiteurs de myéloperoxydase, des compositions pharmaceutiques contenant lesdits inhibiteurs et l'utilisation desdits inhibiteurs pour traiter, par exemple, des maladies cardiovasculaires. (i).
MA37018A 2011-11-11 2014-05-12 2-thiopyrimidinones MA35638B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161558605P 2011-11-11 2011-11-11
PCT/IB2012/055949 WO2013068875A1 (fr) 2011-11-11 2012-10-28 2-thiopyrimidinones

Publications (1)

Publication Number Publication Date
MA35638B1 true MA35638B1 (fr) 2014-11-01

Family

ID=47356235

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37018A MA35638B1 (fr) 2011-11-11 2014-05-12 2-thiopyrimidinones

Country Status (34)

Country Link
US (4) US8835449B2 (fr)
EP (1) EP2776405A1 (fr)
JP (1) JP5731718B2 (fr)
KR (1) KR101650262B1 (fr)
CN (1) CN103917529B (fr)
AP (1) AP2014007621A0 (fr)
AR (1) AR088805A1 (fr)
AU (1) AU2012335220B2 (fr)
BR (1) BR112014011254A2 (fr)
CA (1) CA2853024C (fr)
CL (1) CL2014000996A1 (fr)
CO (1) CO6960543A2 (fr)
CR (1) CR20140179A (fr)
CU (1) CU20140049A7 (fr)
DO (1) DOP2014000098A (fr)
EA (1) EA027324B1 (fr)
EC (1) ECSP14004595A (fr)
GE (1) GEP201706656B (fr)
GT (1) GT201400090A (fr)
HK (1) HK1196603A1 (fr)
IL (2) IL232425A (fr)
MA (1) MA35638B1 (fr)
MD (1) MD20140044A2 (fr)
MX (1) MX351299B (fr)
NI (1) NI201400042A (fr)
PE (1) PE20161219A1 (fr)
PH (1) PH12014501032A1 (fr)
SG (1) SG11201401531RA (fr)
TN (1) TN2014000195A1 (fr)
TW (2) TWI526433B (fr)
UA (1) UA108713C2 (fr)
UY (1) UY34442A (fr)
WO (1) WO2013068875A1 (fr)
ZA (1) ZA201403589B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2386555A1 (fr) 2010-05-13 2011-11-16 Almirall, S.A. Nouveaux dérivés de cyclohéxylamine dotés d'activités agoniste bêta 2 adrénergique et antagoniste muscarinique m3
EP2776405A1 (fr) 2011-11-11 2014-09-17 Pfizer Inc 2-thiopyrimidinones
EP2592078A1 (fr) 2011-11-11 2013-05-15 Almirall, S.A. Nouveaux dérivés de cyclohéxylamine dotés d'activités agonistes bêta 2 adrénergique et antagoniste muscarinique M3
ES2750523T3 (es) 2012-12-18 2020-03-26 Almirall Sa Derivados de ciclohexil y quinuclidinil carbamato que tienen actividades de agonista beta2 adrenérgicos y antagonistas muscarínicos M3
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
US9616063B2 (en) 2014-12-01 2017-04-11 Astrazeneca Ab 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase
WO2016178113A1 (fr) 2015-05-05 2016-11-10 Pfizer Inc. 2-thiopyrimidinones
EP3704127A1 (fr) 2017-11-02 2020-09-09 AiCuris GmbH & Co. KG Nouveaux indole-2-carboxamides à substitution amino-thiazole hautement actifs agissant contre le virus de l'hépatite b (vhb)
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
WO2024038131A1 (fr) 2022-08-18 2024-02-22 Astrazeneca Ab Inhibiteurs de la myéloperoxydase

Family Cites Families (165)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4088751A (en) 1972-04-07 1978-05-09 Colgate-Palmolive Company Self-heating cosmetic
US4171429A (en) 1977-03-29 1979-10-16 Research Corporation Pyrimidine to pyrimidine transformation process
EP0028489B1 (fr) 1979-11-05 1983-10-05 Beecham Group Plc Dérivés d'enzymes et leur préparation
JPS5770693A (en) 1980-10-22 1982-05-01 Fuji Photo Film Co Ltd Desensitizing composition
WO1989010701A1 (fr) 1988-05-05 1989-11-16 Basf Aktiengesellschaft Produits a base de derives d'uracil pour stimuler la croissance et reduire la graisse chez les animaux
KR0155168B1 (ko) 1989-09-29 1998-11-16 미우라 아끼라 6-치환된 아시클로피리미딘 뉴클레오시드 유도체 및 이를 활성성분으로 함유하는 항비루스제
JPH0699170B2 (ja) 1990-01-19 1994-12-07 日東紡績株式会社 耐火被覆材
JPH0525144A (ja) 1991-04-15 1993-02-02 Nissan Chem Ind Ltd ウラシル誘導体及び有害生物防除剤
JPH0525142A (ja) 1991-07-12 1993-02-02 Nissan Chem Ind Ltd ウラシル誘導体及び有害生物防除剤
JPH0543555A (ja) 1991-08-13 1993-02-23 Nissan Chem Ind Ltd ウラシル誘導体及び有害生物防除剤
TW284688B (fr) 1991-11-20 1996-09-01 Takeda Pharm Industry Co Ltd
GB2263639A (en) 1992-01-28 1993-08-04 Merck & Co Inc Substituted pyrimidinones as neurotensin antagonists
JPH063761A (ja) 1992-06-19 1994-01-14 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
US6444656B1 (en) 1992-12-23 2002-09-03 Biochem Pharma, Inc. Antiviral phosphonate nucleotides
KR0151811B1 (ko) 1993-12-21 1998-10-15 강박광 신규한 항바이러스성 2,4-피리미딘디온 유도체 및 그의 제조방법
JP3781200B2 (ja) 1994-04-27 2006-05-31 コニカミノルタホールディングス株式会社 ハロゲン化銀写真感光材料の処理方法
JP3261641B2 (ja) 1994-04-28 2002-03-04 コニカ株式会社 ハロゲン化銀写真感光材料の処理方法
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US6268369B1 (en) 1994-11-16 2001-07-31 Synaptic Pharmaceutical Corporation 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
EE9700209A (et) 1994-11-16 1998-04-15 Synaptic Pharmaceutical Corporation Dihüdropürimidiinid ja nende kasutamine
WO1997017969A1 (fr) 1995-11-16 1997-05-22 Synaptic Pharmaceutical Corporation Dihydropirimidines et leurs emplois
US6228861B1 (en) 1995-11-16 2001-05-08 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US5719190A (en) 1996-02-28 1998-02-17 Pfizer Inc. Inhibition of myeloperoxidase activity
US6172066B1 (en) 1996-05-16 2001-01-09 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US6245773B1 (en) 1996-05-16 2001-06-12 Synaptic Pharmaceutical Corporation 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
EP1021185A4 (fr) 1996-05-16 2005-09-07 Synaptic Pharma Corp Dihydropyrimidines et leurs emplois
WO1997041097A2 (fr) 1996-12-31 1997-11-06 Dr. Reddy's Research Foundation Nouveaux composes heterocycliques, leur procede de preparation, compositions pharmaceutiques les contenant et utilisation de ces composes dans le traitement du diabete et des maladies associees
DE19647380A1 (de) 1996-11-15 1998-05-20 Hoechst Ag 5-Ring-Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
AU735901C (en) 1996-12-05 2004-02-12 Amgen, Inc. Substituted pyrimidinone and pyridone compounds and methods of use
US6096753A (en) 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
TW520362B (en) 1996-12-05 2003-02-11 Amgen Inc Substituted pyrimidine compounds and pharmaceutical composition comprising same
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
DE19731784A1 (de) 1997-07-24 1999-02-04 Bayer Ag Substituierte N-Aryl-N-thioxocarbonyl-sulfonamide
US6130340A (en) 1998-01-13 2000-10-10 President And Fellows Of Harvard College Asymmetric cycloaddition reactions
US6211370B1 (en) 1998-01-13 2001-04-03 Harvard University Asymmetric cycloaddition reactions
AU4084599A (en) 1998-05-18 1999-12-06 Oklahoma Medical Research Foundation Resveratrol inhibition of myeloperoxidase
IL140622A0 (en) 1998-07-06 2002-02-10 Bristol Myers Squibb Co Biphenyl sufonamide derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
CA2252144A1 (fr) 1998-10-16 2000-04-16 University Of Alberta Prodrogues anticancer a action double
DE19918725A1 (de) 1999-04-24 2000-10-26 Bayer Ag Substituierte N-Cyano-sulfonsäureanilide
AU766003B2 (en) * 1999-05-01 2003-10-09 Smithkline Beecham Plc Pyrimidinone compounds
EP1187829B1 (fr) 1999-06-02 2003-12-10 Janssen Pharmaceutica N.V. Derives aminoalkyle substitues (benzodioxane, benzofurane ou benzopyrane)
IT1307786B1 (it) * 1999-07-22 2001-11-19 Bracco Spa Analoghi di ceramidi, processo per la loro preparazione e loro usocome antitumorali.
FR2796945B1 (fr) * 1999-07-30 2002-06-28 Sod Conseils Rech Applic Nouveaux derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinones, leurs procedes de preparation et leur application a titre de medicaments
JP2001131133A (ja) 1999-08-23 2001-05-15 Sankyo Co Ltd 新規ミエロペルオキシダーゼ阻害物質およびその製造方法
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
GB2362101A (en) 2000-05-12 2001-11-14 Astrazeneca Ab Treatment of chronic obstructive pulmonary disease
GB0013655D0 (en) 2000-06-05 2000-07-26 Prolifix Ltd Therapeutic compounds
JO2352B1 (en) 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Compounds for the treatment of non-adaptation of the bottom of the uterus
US6720324B2 (en) 2000-07-05 2004-04-13 Synaptic Pharmaceutical Corporation Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof
AU783403B2 (en) 2000-07-05 2005-10-20 H. Lundbeck A/S Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof
DE60102304T2 (de) 2000-07-14 2005-02-17 Akzo Nobel N.V. Stabilisatorensystem, das hydroxysäuren enthält
DE10034803A1 (de) 2000-07-18 2002-01-31 Bayer Ag Substituierte Sulfonsäureanilide
DE10034800A1 (de) 2000-07-18 2002-01-31 Bayer Ag Substituierte Benzostickstoffheterocyclen
US6562967B2 (en) 2000-07-31 2003-05-13 Brandeis University Kinetic resolutions of chiral 2-and-3-substituted carboxylic acids
WO2002010096A1 (fr) 2000-07-31 2002-02-07 Brandeis University Résolutions cinétiques d'acides carboxyliques chiraux 2- et 3-substitués
WO2003011799A1 (fr) 2000-07-31 2003-02-13 Brandeis University Resolutions par voie cinetique composes chiraux d'acides carboxyliques substitues en position 2 et en position 3
EP2141244A1 (fr) 2000-10-18 2010-01-06 Pharmasset, Inc. Quantification simultanée d'acides nucléiques dans des cellules malades
EP1411954B1 (fr) 2000-10-18 2010-12-15 Pharmasset, Inc. Nucleosides modifies pour traiter des infections virales et une proliferation cellulaire anormale
DE10108995A1 (de) 2001-02-23 2002-09-05 Abbott Gmbh & Co Kg Substituierte Pyrimidinon-Derivate als Liganden von Integrinrezeptoren
WO2002069903A2 (fr) 2001-03-06 2002-09-12 Biocryst Pharmaceuticals, Inc. Nucleosides, leur preparation et utilisation en tant qu'inhibiteurs de polymerases virales d'arn
WO2002090575A1 (fr) 2001-05-08 2002-11-14 Astrazeneca Ab Essai permettant la detection d'inhibiteurs de l'enzyme myeloperoxydase
DK3042894T1 (da) 2001-08-10 2016-11-07 Shionogi & Co Antiviralt middel
AU2002367752A1 (en) 2001-10-03 2003-11-17 Pharmacia Corporation Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade
EP1448534A1 (fr) 2001-10-03 2004-08-25 Pharmacia Corporation Heterocycles unsatures a six chainons en tant qu'inhibiteurs selectifs de la cascade de coagulation
WO2003029216A1 (fr) 2001-10-03 2003-04-10 Pharmacia Corporation Composes heterocycliques a 6 chainons utiles dans l'inhibition selective de la cascade de la coagulation
CA2462601A1 (fr) 2001-10-03 2003-04-10 Pharmacia Corporation Promedicaments de composes polycycliques substitues utiles pour l'inhibition selective de la cascade de la coagulation
AU2003205536A1 (en) 2002-01-11 2003-07-24 Statens Serum Institut Anti-retroviral 5,6-disubstituted acyclopyrimidine nucleoside derivatives
EP1478437B1 (fr) 2002-02-27 2005-08-31 Pfizer Products Inc. Inhibiteurs de l'acetyl-coa-carboxylase
AU2003216591A1 (en) 2002-04-10 2003-10-20 Orichid Chemicals And Pharmaceuticals Limited Amino substituted pyrimidinone derivatives useful in the treatment of inflammation and immunological
AR039385A1 (es) 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
PL374162A1 (en) 2002-05-16 2005-10-03 Bayer Cropscience Gmbh Pyridine carboxamide derivatives and their use as pesticides
EP1394242A3 (fr) 2002-08-07 2004-04-21 Rohm And Haas Company Thiourées cycliques et leur utilisation en tant qu'additifs pour huiles lubrifiantes
EP1394241A1 (fr) 2002-08-07 2004-03-03 Rohm And Haas Company Thioureas comme additifs pour huiles lubrifiantes
WO2004037159A2 (fr) 2002-10-23 2004-05-06 Obetherapy Biotechnology Composes, compositions et methodes permettant de moduler le metabolisme des graisses
US20050096319A1 (en) 2003-02-21 2005-05-05 Balzarini Jan M.R. Identification of compounds that inhibit replication of human immunodeficiency virus
KR20050101221A (ko) 2003-02-21 2005-10-20 트리펩 아베 Ｈｉｖ 복제의 억제를 위한 글리신아미드 유도체
WO2004089927A1 (fr) 2003-04-07 2004-10-21 Cortical Pty Ltd Nouvelles méthodes de traitement des maladies inflammatoires
SE0301232D0 (sv) * 2003-04-25 2003-04-25 Astrazeneca Ab Novel use
US7485604B2 (en) 2003-05-27 2009-02-03 Fujifilm Corporation Lubricant composition and method for using and preparing thereof
US7572581B2 (en) 2003-06-30 2009-08-11 Roche Molecular Systems, Inc. 2′-terminator nucleotide-related methods and systems
US7947817B2 (en) 2003-06-30 2011-05-24 Roche Molecular Systems, Inc. Synthesis and compositions of 2'-terminator nucleotides
NZ547907A (en) 2003-12-22 2010-07-30 Gilead Sciences Inc 4'-Substituted carbovir-and abacavir-derivatives as well as related compounds with HIV and HCV antiviral activity
CN102127053A (zh) 2004-03-15 2011-07-20 武田药品工业株式会社 二肽基肽酶抑制剂
GEP20084421B (en) 2004-05-12 2008-07-10 Pfizer Prod Inc Proline derivatives and their use as dipeptidyl peptidase iv inhibitors
US7745125B2 (en) 2004-06-28 2010-06-29 Roche Molecular Systems, Inc. 2′-terminator related pyrophosphorolysis activated polymerization
US7928207B2 (en) 2004-06-28 2011-04-19 Roche Molecular Systems, Inc Synthesis and compositions of nucleic acids comprising 2′-terminator nucleotides
EP1616874A1 (fr) 2004-07-14 2006-01-18 Universiteit Gent Composés mono- et bicycliques à activité thérapeutique et compositions pharmaceutiques les comprenant
US7485729B2 (en) 2004-08-12 2009-02-03 King Industries, Inc. Organometallic compositions and coating compositions
EP1778778A4 (fr) 2004-08-12 2011-04-27 King Industries Inc Compositions organometalliques et compositions de revetement
US20060100226A1 (en) 2004-09-10 2006-05-11 Sikorski James A 2-Thiopyrimidinones as therapeutic agents
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
WO2006070292A2 (fr) 2004-10-12 2006-07-06 Queen's University At Kingston Composes de pyrimidine en tant qu'agents anti-ictogeniques et/ou agents anti-epileptogeniques
SE0402591D0 (sv) 2004-10-25 2004-10-25 Astrazeneca Ab Novel use
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
US20060194821A1 (en) 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
EP1731911A1 (fr) 2005-06-07 2006-12-13 Institut National De La Sante Et De La Recherche Medicale (Inserm) Procédé utile pour la détection d'encéphalopathies
US7399786B2 (en) 2005-06-30 2008-07-15 Bexel Pharmaceuticals, Inc. Derivatives of amino acids for treatment of obesity and related disorders
EP1920073A2 (fr) 2005-07-01 2008-05-14 Dako Denmark A/S Procede de visualisation simultanee de multiples cibles biologiques
WO2007045998A2 (fr) 2005-07-01 2007-04-26 Dako Denmark A/S Paires de bases d'acides nucleiques
ATE518853T1 (de) 2005-08-12 2011-08-15 Schering Corp Verbindungen zur behandlung entzündlicher erkrankungen
BRPI0620718A2 (pt) 2005-10-28 2011-11-22 Takeda Pharmaceutical agente para a proteção do páncreas, e, uso de uma droga para a redução de glicose
WO2007064797A2 (fr) 2005-11-30 2007-06-07 Vertex Pharmaceuticals Incorporated Inhibiteurs de c-met et leurs utilisations
DE102006000649A1 (de) 2006-01-03 2007-07-05 Degussa Gmbh Universell einsetzbare Zusammensetzungen
DE102006000651A1 (de) 2006-01-03 2007-07-12 Degussa Gmbh Präparation aus Ionischen Flüssigkeiten und Harzen
JP5025142B2 (ja) 2006-02-27 2012-09-12 株式会社東芝 モータ制御装置
JP5025144B2 (ja) 2006-02-28 2012-09-12 Ｊｘ日鉱日石エネルギー株式会社 内燃機関用潤滑油組成物
UY30267A1 (es) 2006-04-13 2007-11-30 Astrazeneca Ab Nuevos derivados de la tioxantina , composiciones farmacéuticas que los contienen, procedimientos de preparacion y aplicaciones
SI2463283T1 (sl) 2006-04-20 2014-09-30 Pfizer Products Inc. Kondezirane fenil amino heterociklične spojine za preprečevanje in zdravljenje bolezni, ki jih posreduje glukokinaza
TW200808649A (en) 2006-05-31 2008-02-16 Du Pont Process for purifying perfluorinated products
WO2007142577A1 (fr) 2006-06-05 2007-12-13 Astrazeneca Ab Dérivé de pyrrolo[3,2-d]pyrimidine-4-un en tant qu'inhibiteur de la myéloperoxydase
TW200804383A (en) 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
PT2048145E (pt) 2006-08-04 2011-01-14 Toyama Chemical Co Ltd Agente incrementando a actividade da proteína quinase c, contendo um derivado de um éter alquílico, ou um seu sal
WO2008023249A1 (fr) 2006-08-24 2008-02-28 Chemfit Speciality Chemicals (Pty) Ltd Composition de poly(chlorure de vinyle)
WO2008070447A2 (fr) 2006-11-21 2008-06-12 Smithkline Beecham Corporation Composés anti-viraux
JP2010511035A (ja) 2006-11-29 2010-04-08 ファイザー・プロダクツ・インク スピロケトンアセチルＣｏＡカルボキシラーゼ阻害剤
US20080153697A1 (en) 2006-12-22 2008-06-26 E. I. Dupont De Nemours And Company Mixtures of ammonia and ionic liquids
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
US8633186B2 (en) 2007-06-08 2014-01-21 Senomyx Inc. Modulation of chemosensory receptors and ligands associated therewith
US8354421B2 (en) 2007-06-29 2013-01-15 Korea Research Insitute Of Chemical Technology HIV reverse transcriptase inhibitors
AR067181A1 (es) 2007-06-29 2009-09-30 Gilead Sciences Inc Inhibidores de transcriptasa inversa de hiv, composicion farmaceutica, uso del compuesto para preparar un medicamento, agente de combinacion farmaceutica y metodo de inhibicion de la replicacion de un retrovirus
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
JP5043555B2 (ja) 2007-08-08 2012-10-10 株式会社カネカ 硬化性組成物
US20090054468A1 (en) 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938
US20090053176A1 (en) 2007-08-23 2009-02-26 Astrazeneca Ab New Combination 937
EP2217588A4 (fr) 2007-11-02 2013-12-04 Methylgene Inc Inhibiteurs de l'histone déacétylase
GB0722680D0 (en) 2007-11-19 2007-12-27 Topotarget As Therapeutic compounds and their use
JP2009167179A (ja) 2007-12-21 2009-07-30 Daiichi Sankyo Co Ltd 環状アミン化合物を含有する医薬
US20110105488A1 (en) 2008-03-21 2011-05-05 Chlorion Pharma, Inc. Substituted pyrrolidine and piperidine compounds, derivatives thereof, and methods for treating pain
US8236446B2 (en) 2008-03-26 2012-08-07 Ada Technologies, Inc. High performance batteries with carbon nanomaterials and ionic liquids
EP2268288A4 (fr) 2008-04-15 2012-05-30 Rfs Pharma Llc Dérivés nucléosidiques destinés au traitement d infections par un virus de la famille des caliciviridae, y compris d infections par le norovirus
GB2472554B (en) 2008-05-05 2012-12-05 Ada Technologies Inc High performance carbon nanocomposites for ultracapacitors
EP2297164A1 (fr) 2008-05-28 2011-03-23 Pfizer Inc. Inhibiteurs de la pyrazolospirocétone acétyl-coa carboxylase
ES2545231T3 (es) 2008-05-28 2015-09-09 Pfizer Inc. Inhibidores de pirazoloespirocetona acetil-CoA carboxilasa
CA2729581A1 (fr) 2008-07-29 2010-02-04 Pfizer Inc. Heteroaryles fluores
EA018492B1 (ru) 2008-08-28 2013-08-30 Пфайзер Инк. Диоксабицикло[3.2.1]октан-2,3,4-триольные производные
GB0818063D0 (en) * 2008-10-02 2008-11-05 Univ Dundee Compounds
JP5206367B2 (ja) 2008-11-27 2013-06-12 コニカミノルタエムジー株式会社 ウレア化合物を含む有機圧電材料
WO2010086820A1 (fr) 2009-02-02 2010-08-05 Pfizer Inc. Dérivés de 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazépin-6(5h)-yl)phényle
EP2406253B1 (fr) 2009-03-11 2013-07-03 Pfizer Inc. Dérivés de benzofuranyle utilisés comme inhibiteurs de la glucokinase
CA2754685A1 (fr) 2009-03-11 2010-09-16 Pfizer Inc. Indazole amides substitues
CA2754523A1 (fr) 2009-03-20 2010-09-23 Pfizer Inc. 3-oxa-7-azabicyclo[3,3.1]nonanes
KR20120070539A (ko) 2009-04-23 2012-06-29 인베이스크 테라퓨틱스, 인크. 심혈관 질환 치료용 조성물 및 방법
US20100272783A1 (en) 2009-04-24 2010-10-28 Novabay Pharmaceuticals, Inc. Methods of Treating Infections of the Nail
JP2012526097A (ja) 2009-05-08 2012-10-25 ファイザー・インク Ｇｐｒ１１９調節因子
EP2427448A1 (fr) 2009-05-08 2012-03-14 Pfizer Inc. Modulateurs du gpr119
US20120122948A1 (en) 2009-05-27 2012-05-17 Universite Libre De Beuxelles 3-alkyl-5-fluoroindole derivatives as myeloperoxidase inhibitors
WO2010138901A1 (fr) 2009-05-29 2010-12-02 Biogen Idec Ma Inc Composés contenant de l'acide carboxylique, leurs dérivés et procédés d'utilisation associés
AU2010255422B2 (en) 2009-06-05 2014-04-10 Pfizer Inc. 1- ( piperidin-4-yl) -pyrazole derivatives as GPR 119 modulators
AU2010266018B2 (en) 2009-06-25 2014-01-09 Alkermes Pharma Ireland Limited Heterocyclic compounds for the treatment of neurological and psychological disorders
EP2445343B1 (fr) 2009-06-25 2021-08-04 Alkermes Pharma Ireland Limited Promédicaments de composés nh acides
WO2011003018A2 (fr) 2009-07-01 2011-01-06 Cornell University 2-désoxy-lactones halogénées, 2'-désoxy-nucléosides, et leurs dérivés
WO2011005611A1 (fr) 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Agonistes du récepteur de la neuromédine u et leurs utilisations
DE102009037300A1 (de) 2009-08-14 2011-02-17 Merck Patent Gmbh Tetracyanoborate als Schmierstoffe
EP2501696B1 (fr) 2009-10-15 2016-12-28 Guerbet Agents pour l'imagerie et leur utilisation pour le diagnostic in vivo de maladies neurodégénératrices, notamment la maladie d'alzheimer et des maladies apparentées
WO2011057220A2 (fr) 2009-11-09 2011-05-12 Northwestern University Compositions et méthodes pour traiter les lymphomes
FR2953145B1 (fr) 2009-11-30 2013-07-19 Inst Francais Du Petrole Solution absorbante contenant un inhibiteur de degradation derive de la pyrimidine ou de la triazine et procede d'absorption de composes acides contenus dans un effluent gazeux
WO2011094890A1 (fr) 2010-02-02 2011-08-11 Argusina Inc. Dérivés phénylalanines et leur utilisation comme modulateurs non peptidiques du récepteur de glp-1
US20130085133A1 (en) 2010-02-08 2013-04-04 Sourthern Research Institute Office of Commercialization and Intellectual Prop. Anti-viral treatment and assay to screenfor anti-viral agent
JP5816635B2 (ja) 2010-03-05 2015-11-18 カリオファーム セラピューティクス，インコーポレイテッド 核輸送調節剤およびその使用
NZ604423A (en) 2010-06-24 2015-01-30 Alkermes Pharma Ireland Ltd Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
WO2012016133A2 (fr) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Inhibiteurs de la ros1 kinase pour le traitement de glioblastome et d'autres cancers déficients en p53
ES2352926B1 (es) 2010-12-07 2012-01-12 Universidad De Granada Fenucil deuterado y derivados, procedimiento para su preparación y usos de los mismos.
EP2776405A1 (fr) * 2011-11-11 2014-09-17 Pfizer Inc 2-thiopyrimidinones
JP6003761B2 (ja) 2013-03-27 2016-10-05 富士ゼロックス株式会社 送風管、送風装置及び画像形成装置
WO2016178113A1 (fr) * 2015-05-05 2016-11-10 Pfizer Inc. 2-thiopyrimidinones

Also Published As

Publication number Publication date
UA108713C2 (xx) 2015-05-25
EP2776405A1 (fr) 2014-09-17
US8835449B2 (en) 2014-09-16
AU2012335220A1 (en) 2014-05-01
MD20140044A2 (ro) 2014-08-31
KR101650262B1 (ko) 2016-08-22
ECSP14004595A (es) 2015-11-30
PH12014501032A1 (en) 2014-10-20
GEP201706656B (en) 2017-04-25
AR088805A1 (es) 2014-07-10
IL249039B (en) 2018-07-31
IL232425A (en) 2016-11-30
TW201332979A (zh) 2013-08-16
TW201518281A (zh) 2015-05-16
JP2014533261A (ja) 2014-12-11
GT201400090A (es) 2015-09-04
CA2853024A1 (fr) 2013-05-16
NZ624453A (en) 2015-12-24
WO2013068875A1 (fr) 2013-05-16
DOP2014000098A (es) 2014-07-31
IL249039A0 (en) 2017-01-31
CU20140049A7 (es) 2014-08-28
TWI480269B (zh) 2015-04-11
PE20161219A1 (es) 2016-11-17
US20160304469A1 (en) 2016-10-20
UY34442A (es) 2013-06-28
CL2014000996A1 (es) 2014-07-04
SG11201401531RA (en) 2014-07-30
US20140288049A1 (en) 2014-09-25
MX351299B (es) 2017-10-10
CR20140179A (es) 2014-06-12
US9399626B2 (en) 2016-07-26
CN103917529B (zh) 2016-08-17
NI201400042A (es) 2014-10-01
US20130123230A1 (en) 2013-05-16
CN103917529A (zh) 2014-07-09
ZA201403589B (en) 2015-06-24
KR20140089603A (ko) 2014-07-15
US9873673B2 (en) 2018-01-23
US20130296351A1 (en) 2013-11-07
EA027324B1 (ru) 2017-07-31
CO6960543A2 (es) 2014-05-30
CA2853024C (fr) 2017-08-22
TN2014000195A1 (fr) 2015-09-30
US8841314B2 (en) 2014-09-23
TWI526433B (zh) 2016-03-21
EA201490688A1 (ru) 2014-10-30
JP5731718B2 (ja) 2015-06-10
MX2014005721A (es) 2014-05-28
HK1196603A1 (zh) 2014-12-19
AU2012335220B2 (en) 2017-06-01
AP2014007621A0 (en) 2014-05-31
BR112014011254A2 (pt) 2017-05-16
IL232425A0 (en) 2014-06-30

Similar Documents

Publication Publication Date Title
MA35638B1 (fr) 2-thiopyrimidinones
PH12017501306A1 (en) Inhibitors of histone demethylases
MA39211B1 (fr) Composés tricycliques comme agents anti-cancers
MA35661B1 (fr) Inhibiteurs de pak pour le traitement de troubles de prolifération cellulaire
MX2022009942A (es) Composiciones farmaceuticas que comprenden epa y un agente cardiovascular y metodos para utilizar el mismo.
MA34248B1 (fr) 5-fluoro-1h-pyrazolopyridines substituées et leur utilisation
FR3021970B1 (fr) Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs
MA35920B1 (fr) Composés destinés au traitement de l'amyotrophie spinale
MX2013008192A (es) Inhibidores de bace-2 para tratamiento de transtornos metabolicos.
MA47356A1 (fr) Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases
TN2016000040A1 (fr) Inhibiteurs de porc2 et procedes pour leur utilisation
MA38190A2 (fr) Inhibiteurs d'autotaxine
MA33457B1 (fr) L-sérine pour son utilisation en tant que médicament pour prévenir et/ou traiter une réaction inflammatoire de la peau
MA39170A1 (fr) Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer
MA38253A1 (fr) Compositions comprenant de la vortioxétine et du donépézil
MA38925B1 (fr) Dérivés de phénylalanine substitués
FR2961402B1 (fr) Compositions contenant des arabinoxylo-oligosaccharides et leurs utilisations
EA201591180A1 (ru) Составы ингибитора lfa-1
EA201491455A1 (ru) ЭФФЕКТОРЫ β-АРРЕСТИНА, КОМПОЗИЦИИ, ИХ СОДЕРЖАЩИЕ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EA201301083A1 (ru) Комплексные соединения железа(iii) для лечения и профилактики симптомов железодефицита и железодефицитной анемии
MA31385B1 (fr) Utilisation d'inhibiteurs de hdac pour le traitement de la destruction osseuse
MA33513B1 (fr) Utilisation d'une composition pour le traitement et/ou la prophylaxie des plantes et dite composition
MA44025B1 (fr) Inhibiteurs de pde9 pour le traitement de maladies périphériques
MA38473B1 (fr) (benzyl-cyano-méthyl)-amides substitués de l'acide 2-aza-bicyclo[2.2.1]heptane-3-carboxylique utilisés comme inhibiteurs de la cathépsine c
SA515360233B1 (ar) مثبطات إنزيمات هستون ديميثيلاز